NTHI Overview

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. It is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is developing novel drug delivery methods to be used in combination with novel drug candidates. The Company has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).

Wall Street analysts forecast NTHI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTHI is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

NeOnc Technologies Holdings Inc revenue for the last quarter amounts to 0.00 USD, decreased

NeOnc Technologies Holdings Inc. EPS for the last quarter amounts to -0.45 USD, increased 275.00

NeOnc Technologies Holdings Inc (NTHI) has 3 emplpoyees as of March 10 2026.

Today NTHI has the market capitalization of 220.79M USD.